[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 157
6. Kycko A, Reichert M: [Current views on the mechanism of oncogenic cell transformation in ovine pulmonary adenocarcinoma]. Postepy Hig Med Dosw (Online); 2007 Dec 10;61:797-804
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current views on the mechanism of oncogenic cell transformation in ovine pulmonary adenocarcinoma].
  • Lung cancer is the most frequently diagnosed of all the human neoplasms leading to death.
  • Because twenty percent of cases are not associated with cigarette smoking, other causes and methods of early diagnosis are being sought.
  • Bronchioloalveolar cancer, which is a subtype of the most common primary lung cancer, adenocarcinoma, is very similar to ovine pulmonary adenocarcinoma (OPA), a naturally occurring lung cancer in sheep.
  • The virus induces neoplastic transformation of secretory epithelial cells of the lung, i.e. alveolar type II pneumocytes and Clara cells.
  • JSRV's tropism for these cells is connected with viral LTR regions interacting with cellular factors that play major roles in the expression of lung-specific genes, e.g. those of surfactant proteins.
  • Morphological and histological similarities with human bronchioloalveolar cancer and the possibility of experimental induction of the tumor in animals makes OPA a good model for the study of oncogenesis and target therapy of lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097338.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  • [Number-of-references] 55
  •  go-up   go-down


7. Raz DJ, Zell JA, Karnezis AN, Odisho A, Ignatius Ou SH, Anton-Culver H, Jablons DM: Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer. J Thorac Oncol; 2006 Nov;1(9):943-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer.
  • INTRODUCTION: Cytology is commonly used to diagnose non-small cell lung cancer (NSCLC) but is an inaccurate means of diagnosis of bronchioloalveolar carcinoma (BAC).
  • The aims of this study were to calculate the sensitivity and specificity of cytologic diagnosis of BAC and to estimate the misclassification of BAC as other subtypes of NSCLC.
  • METHODS: Preoperative fine-needle aspiration cytology diagnoses were compared to histology diagnoses in 222 patients, including 51 patients with pure or mixed BAC, who underwent lung resection for NSCLC at our institution since 1999.
  • RESULTS: The sensitivity and specificity of a cytologic diagnosis of BAC were 12% and 99%, respectively.
  • Based on cytologic diagnosis, 63% of BAC was misclassified as adenocarcinoma, and 18% was misclassified as undifferentiated NSCLC.
  • CONCLUSIONS: Diagnosis of NSCLC by cytology alone results in significant misclassification of BAC, most commonly as adenocarcinoma or undifferentiated NSCLC.
  • Because patients with BAC respond differently to certain treatments such as endothelial growth factor receptor inhibitors and surgical resection of multifocal lung cancer, misclassification of BAC may have important therapeutic implications.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Cohort Studies. Cytodiagnosis / classification. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Preoperative Care / methods. Probability. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1987 Nov-Dec;31(6):717-25 [2827409.001]
  • [Cites] J Clin Oncol. 2005 May 10;23 (14 ):3279-87 [15886315.001]
  • [Cites] Acta Cytol. 1985 Sep-Oct;29(5):887-94 [2996275.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):29-34 [11241263.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):14-6 [15272525.001]
  • [Cites] J Cardiovasc Surg (Torino). 2001 Apr;42(2):261-7 [11398743.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):47-52 [16503085.001]
  • [Cites] Diagn Cytopathol. 1998 Apr;18(4):301-6 [9557268.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Nov;126(5):1597-602 [14666039.001]
  • [Cites] Oncologist. 2005 Oct;10 Suppl 2:23-9 [16272456.001]
  • [Cites] Cancer. 2001 Apr 25;93(2):124-31 [11309778.001]
  • [Cites] Jpn J Clin Oncol. 2006 Feb;36(2):69-75 [16449241.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1255-62 [16766595.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1728-33 [15511463.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):44-50 [15272529.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):988-93; discussion 993-4 [12400733.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):413-8 [16365180.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3288-93 [15886316.001]
  • [Cites] Clin Lung Cancer. 2006 Mar;7(5):313-22 [16640802.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3698-704 [16778095.001]
  • (PMID = 17409976.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093708-04; United States / NCI NIH HHS / CA / R01 CA093708-02; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / T32 CA108462; United States / NCI NIH HHS / CA / T32 CA108462-01
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Mazziotti S, Celona A, Gaeta M: Usefulness of heavily T2-weighted magnetic resonance imaging in the diagnosis of alveolar lung metastases from pancreas mucinous adenocarcinoma. J Thorac Imaging; 2008 Feb;23(1):44-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of heavily T2-weighted magnetic resonance imaging in the diagnosis of alveolar lung metastases from pancreas mucinous adenocarcinoma.
  • We report the case of a patient with pancreatic adenocarcinoma and mucinous air-space metastases, in which the diagnosis was suspected at magnetic resonance using heavily T2-weighted images obtained with magnetic resonance hydrographic sequences.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology. Pulmonary Alveoli / pathology
  • [MeSH-minor] Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347520.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


9. Noguchi M, Minami Y, Iijima T, Matsuno Y: Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int; 2005 Jan;55(1):8-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria.
  • Using 32 small adenocarcinomas of the lung including bronchioloalveolar carcinoma (BAC), the reproducibility of diagnosis by the modified diagnostic criteria for small adenocarcinoma (Cancer 75; 2844, 1995) and the effectiveness of an educational program for 27 volunteer general pathologists were examined.
  • The average coincidence rate of the diagnosis before and after the program was 42.4% and 56.6%, respectively.
  • In contrast, the average coincidence rate of six lung cancer specialists was 71.4%, and this was significantly higher than that for general pathologists after the program (P < 0.05).
  • When the cases were divided into two groups (in situ adenocarcinoma (BAC and BAC with alveolar collapse) and early invasive adenocarcinoma), the average coincidence rate for the general pathologists after the program increased to 85.3%, which was significantly higher than that before the program (80.3%; P < 0.05).
  • This trial was thought to provide a theoretical background for the histological diagnosis of peripheral type adenocarcinoma of the lung and to justify the existing diagnostic criteria.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Lung Neoplasms / diagnosis. Pathology, Surgical / education
  • [MeSH-minor] Diagnosis, Differential. Humans. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660697.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


10. Nakamura N, Kobayashi K, Nakamoto M, Kohno T, Sasaki H, Matsuno Y, Yokota J: Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene; 2006 Jul 13;25(30):4245-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma.
  • To identify tumor markers and differentiation markers for lung adenocarcinoma (AdC), we analysed expression profiles of 14,500 genes against three cases of type II alveolar epithelial cells, bronchiolar epithelial cells, and bronchial epithelial cells, respectively, and 10 cases of AdC cells isolated by laser capture microdissection.
  • Hierarchical clustering analysis indicated that AdC cells and noncancerous lung epithelial cells are significantly different in their expression profiles, and that different sets of differentiation markers are expressed among alveolar, bronchiolar and bronchial epithelial cells.
  • Nine genes were identified as being highly expressed in AdC cells, but not expressed in noncancerous lung epithelial cells.
  • Sixteen genes were identified as differentiation markers for lung epithelial cells.
  • Real-time RT-PCR analysis of 45 lung AdC cases further revealed that expression of four tumor markers in AdC cells was significantly higher than that in noncancerous lung cells and that expression of ten differentiation markers was retained in a considerable fraction of lung AdC cases.
  • Similarities and differences in expression profiles between normal epithelial cells from different lung respiratory compartments and AdC cells demonstrated in this study will be informative for the molecular diagnosis of lung AdC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biomarkers, Tumor. Cell Differentiation. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491115.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Lin DM, Ma Y, Zheng S, Liu XY, Zou SM, Wei WQ: Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol; 2006 06;21(6):627-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma.
  • BAC is a common pattern in conventional lung adenocarcinoma.
  • As a result, it was difficult to evaluate the prognosis on this type of lung adenocarcinoma.
  • Though the 1999 WHO classification of BAC provides a useful framework, it does not provide detailed enough information to predict prognosis in lung adenocarcinomas with BAC feature.
  • The aim of this study was to address the prognostic value of bronchioloalveolar carcinoma (BAC) component in lung adenocarcinoma.
  • Ninety-one consecutive surgically treated patients with adenocarcinoma exhibiting various degrees of BAC features and complete follow-up records were retrospectively studied.
  • In lung adenocarcinoma, the BAC component may prove to be useful to predict the outcome of the patients, and the percentage of BAC pattern and pathological stage appear to be two independent prognostic factors.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528673.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Zell JA, Ou SH, Ziogas A, Anton-Culver H: Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol; 2006 Aug;17(8):1255-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis.
  • BACKGROUND: It has been suggested that the current staging system does not accurately reflect survival outcomes for advanced bronchiolo-alveolar carcinoma (BAC) patients.
  • Overall survival (OS) and lung cancer-specific survival (LCSS) univariate analyses were conducted using the Kaplan-Meier method.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766595.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Uji M, Matsushita H, Watanabe T, Suzumura T: [A case of primary Sjögren's syndrome complicated with lung adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2007 May;45(5):409-12
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary Sjögren's syndrome complicated with lung adenocarcinoma].
  • The serum value of carcinoembryonic antigen was highly elevated, so we made a presumed diagnosis of primary non-small lung cancer.
  • The elevated values of serum antibodies against SS-A and SS-B and further examinations resulted in a definitive diagnosis of primary Sjögren's syndrome.
  • Autopsy revealed that the mass shadow was a primary lung adenocarcinoma.
  • Those lesions had bullae, emphysema, and alveolar septae thickened by infiltration of lymphoplasmacytic cells.
  • We raise a possibility that lung cancer might derive from cystic lesions associated with Sjögren's syndrome.
  • [MeSH-major] Adenocarcinoma / complications. Lung Neoplasms / complications. Sjogren's Syndrome / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554985.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


1
Advertisement
4. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M: Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol; 2005 May 10;23(14):3279-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.
  • PURPOSE: To review recent advances in pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC).
  • METHODS: A pathology/CT review panel of pathologists and radiologists met during a November 2004 International Association for the Study of Lung Cancer/American Society of Clinical Oncology consensus workshop in New York.
  • The purpose was to determine if existing data was sufficient to propose modification of criteria for adenocarcinoma and BAC as newly published in the 2004 WHO Classification of Lung Tumors, and to address the pathologic/radiologic concept of diffuse/multicentric BAC.
  • Most lung adenocarcinomas with a BAC pattern are not pure BAC, but rather adenocarcinoma, mixed subtype with invasive patterns.
  • The percent of BAC versus invasive components in lung adenocarcinomas appears to be prognostically important.
  • While recognition of a BAC component is possible, the diagnosis of BAC with exclusion of invasive adenocarcinoma cannot be made by small biopsy or cytology specimens.
  • CONCLUSION: There is a need to work toward a mutual understanding and consensus between pathologists, clinicians, and researchers with the use of the term BAC versus adenocarcinoma.
  • Hopefully, this work will allow definition of a category of adenocarcinoma, mixed subtype with predominant BAC/minimal invasion and a favorable prognosis.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886315.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


15. Izquierdo-Garcia FM, Moreno-Mata N, Herranz-Aladro ML, Cañizares MA, Alvarez-Fernandez E: Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment. Histol Histopathol; 2010 10;25(10):1287-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment.
  • Rhabdoid tumor, included in the WHO classification among large cell carcinomas of the lung, is an uncommon type of lung carcinoma with poor prognosis.
  • We report a series of 7 cases of lung carcinomas with rhabdoid component in 10% and 80% of the tumor.
  • The associated tumor was adenocarcinoma in 3 cases--one of them with focal micropapillary pattern--large cell carcinoma in 2 cases, squamous cell carcinoma in 1 case and pleomorphic carcinoma in 1 case.
  • Alveolar trapping inside the tumor was present in 3 cases--a phenomenon not well studied in lung carcinomas and also not reported in tumors with rhabdoid component.
  • Five patients died because of the tumor within 2 to 31 months after diagnosis, one of myocardial infarction and only one is alive and disease free 123 months after the diagnosis.
  • In summary, we describe 7 new cases of this uncommon lung tumor with aggressive clinical course, associated with infrequent histological types in nonrhabdoid component and with alveolar trapping, a nondescribed finding.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Pulmonary Alveoli / pathology. Rhabdoid Tumor / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712013.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Liu S, Cheng H, Yao S, Wang C, Han G, Li X, Liu C: The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. Ann Nucl Med; 2010 Aug;24(7):541-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features.
  • OBJECTIVE: The goal of our study was to demonstrate the clinical usefulness of positron emission tomography/computed tomography (PET/CT) for adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, through evaluating the relationship between the intrathoracic lymph node metastases and maximum standardized uptake value (SUVmax), tumor size of the primary tumor and the ratio of BAC component and analysing the correlation of SUVmax, tumor size and the ratio of BAC component.
  • Forty-five patients with focal peripheral lung adenocarcinoma with BAC features were included in this study and underwent the PET/CT scan.
  • The diagnosis of the lesion was made by surgical histopathology.
  • CONCLUSIONS: PET/CT would be clinically useful for adenocarcinoma with BAC features, because SUVmax obtained by PET/CT can predict the incidence of intrathoracic lymph node metastases at preoperative stages and even for inoperable patients.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / complications. Positron-Emission Tomography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614257.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Voigt K, Brügmann M, Huber K, Dewar P, Cousens C, Hall M, Sharp JM, Ganter M: PCR examination of bronchoalveolar lavage samples is a useful tool in pre-clinical diagnosis of ovine pulmonary adenocarcinoma (Jaagsiekte). Res Vet Sci; 2007 Dec;83(3):419-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCR examination of bronchoalveolar lavage samples is a useful tool in pre-clinical diagnosis of ovine pulmonary adenocarcinoma (Jaagsiekte).
  • Ovine pulmonary adenocarcinoma (OPA) is a contagious lung tumour of sheep caused by Jaagsiekte sheep retrovirus (JSRV).
  • [MeSH-major] Bronchoalveolar Lavage Fluid / virology. Jaagsiekte sheep retrovirus / isolation & purification. Polymerase Chain Reaction / veterinary. Pulmonary Adenomatosis, Ovine / diagnosis
  • [MeSH-minor] Animals. Bronchoalveolar Lavage / economics. Bronchoalveolar Lavage / veterinary. Female. Macrophages, Alveolar / virology. Male. Predictive Value of Tests. Sensitivity and Specificity. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418304.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Ishizuka T, Endo S, Tsubochi H, Nakano T, Miwa C, Watanabe K, Koyama S, Nokubi M, Sohara Y: [Mucinous bronchiolo-alveolar cell carcinoma with marked serum elevation of CA19-9: report of a case]. Kyobu Geka; 2009 Jun;62(6):509-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous bronchiolo-alveolar cell carcinoma with marked serum elevation of CA19-9: report of a case].
  • The pathologic study obtained by a transbronchial tumor biopsy revealed a mucinous adenocarcinoma The patient underwent video-assisted thoracoscopic right middle and lower bi-lobectomies with nodal sampling.
  • Postoperative course was uneventful Pathologic study revealed an adenocarcinoma with mixed subtypes, predominantly composed of mucinous bronchiolo-alveolar cell carcinoma (BAC).
  • Clinico-pathologic features of the lung cancer patients with serum elevation of CA19-9 and CA19-9 positivity in the cancer cells was discussed.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522216.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


24. Isobe K, Hata Y, Sugino K, Takai Y, Shibuya K, Homma S: [Usefulness of FDG-PET for diagnosis of lung cancer associated with interstitial pneumonia]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):278-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of FDG-PET for diagnosis of lung cancer associated with interstitial pneumonia].
  • AIM: The aim of this study was to demonstrate the usefulness of FDG-PET for diagnosis of lung cancer associated with interstitial pneumonia (IP), clinicopathologically.
  • SUBJECTS AND METHODS: 32 patients with IP-associated lung cancer (IP-LC group) and 26 patients with IP not associated with lung cancer (IP group) underwent 18-fluorodeoxyglucose positron emission tomography (FDG-PET) for diagnostic procedure from April 2004 through October 2007.
  • Standard uptake values (SUV) were compared between IP and lung cancer fields in two groups.
  • In addition, expression of Glut-1, MIB-1, and p53 in the resected lung tissues (n=10) were analyzed.
  • RESULTS: There was a significant difference in SUVs between lung cancer fields and IP fields.
  • However, it was difficult to distinguish the fields of well-differentiated adenocarcinoma from IP by SUV.
  • Red blood cells in the vessels along the alveolar walls, hyperplastic alveolar type II cells, and squamous metaplastic cells in the fibrotic lung tissues revealed expression of Glut-1.
  • In addition, hyperplastic alveolar type II cells and metaplastic cells also revealed expression of MIB-1 and p53.
  • CONCLUSION: The elevation of SUV in IP fields can be caused by neovascularization and/or hyperplasia of alveolar type II cells and metaplastic cells in the fibrotic lesions.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Diseases, Interstitial / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455956.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


25. Schoen K, Block G, Newell SM, Coronado GS: Hypercalcemia of malignancy in a cat with bronchogenic adenocarcinoma. J Am Anim Hosp Assoc; 2010 Jul-Aug;46(4):265-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcemia of malignancy in a cat with bronchogenic adenocarcinoma.
  • Histopathology diagnosed a bronchogenic adenocarcinoma, and calcium levels returned to normal limits after excision of the mass.
  • While bronchogenic adenocarcinoma has been a suspected cause for hypercalcemia in cats, to the authors' knowledge, this is the first proven account.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / veterinary. Cat Diseases / diagnosis. Hypercalcemia / veterinary. Lung Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610700.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Collins AM, Ridgway PF, Killeen RP, Dodd JD, Tolan M: Congenital cystic adenomatoid malformation of the lung: hazards of delayed diagnosis. Respirology; 2009 Sep;14(7):1058-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital cystic adenomatoid malformation of the lung: hazards of delayed diagnosis.
  • Lung-sparing surgery, in the form of two segmentectomies and a non-anatomical resection, was performed in order to avoid pneumonectomy.
  • [MeSH-major] Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cystic Adenomatoid Malformation of Lung, Congenital / diagnosis. Delayed Diagnosis
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / etiology. Adult. Humans. Lung / abnormalities. Lung / pathology. Lung / radiography. Lung Neoplasms / etiology. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740267.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


27. Parshin VD, Grigor'eva SP, Mirzoian OS, Fedorov DN: [Surgical treatment of bronchiolo-alveolar cancer]. Khirurgiia (Mosk); 2009;(12):4-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of bronchiolo-alveolar cancer].
  • Bronchioloalveolar cancer (BAC) belongs to a high- grade differentiated lung adenocarcinoma, localizes in peripheral parts of the lung and demonstrates an intraalveolar growth.
  • It comprised 0,5% of the whole amount of patients operated on lung cancer.
  • Long-term treatment results are somewhat better then of other forms of non-small cell carcinoma of lung: of 21 radically operated patients, 11 are alive.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037505.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


28. Gupta R, McKenna R Jr, Marchevsky AM: Lessons learned from mistakes and deferrals in the frozen section diagnosis of bronchioloalveolar carcinoma and well-differentiated pulmonary adenocarcinoma: an evidence-based pathology approach. Am J Clin Pathol; 2008 Jul;130(1):11-20; quiz 146
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons learned from mistakes and deferrals in the frozen section diagnosis of bronchioloalveolar carcinoma and well-differentiated pulmonary adenocarcinoma: an evidence-based pathology approach.
  • The frozen section diagnosis of lung nodules is difficult because inflammatory atypia and histologic artifacts can simulate a malignancy.
  • Positive likelihood ratios allowed for identification of the 5 most useful pathologic features for the diagnosis of AC: multiple growth patterns, anisocytosis, atypia more than 75%, macronucleoli, and atypical mitoses.
  • Granulomas favored the diagnosis of RA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Diagnostic Errors. Frozen Sections / methods. Lung Neoplasms / diagnosis
  • [MeSH-minor] Aspergillosis / diagnosis. Aspergillosis / pathology. Bayes Theorem. Diagnosis, Differential. Evidence-Based Medicine. Humans. Pneumonia / diagnosis. Pulmonary Sclerosing Hemangioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550465.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Gordon IO, Sitterding S, Mackinnon AC, Husain AN: Update in neoplastic lung diseases and mesothelioma. Arch Pathol Lab Med; 2009 Jul;133(7):1106-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in neoplastic lung diseases and mesothelioma.
  • CONTEXT: Lung cancer is a common disease frequently seen by the surgical pathologist.
  • Although secondary to improvements in screening and radiologic techniques and aggressive resection of small pulmonary nodules, the diagnosis of preneoplastic lesions is increasing in frequency and importance.
  • Consequently, a greater understanding of their role in the development of lung carcinoma is needed for optimal patient care.
  • Two lesions often encountered as small pulmonary nodules are bronchioloalveolar carcinoma and adenocarcinoma, which can be challenging to distinguish.
  • Recently, updates to the TNM classification of non-small cell lung carcinoma have been reported that directly impact prognosis and treatment algorithms.
  • OBJECTIVE: To present recent advances in our understanding of neoplastic lung diseases and mesothelioma and to describe how these advances relate to the current practice of pulmonary pathology.
  • CONCLUSIONS: It is important for the surgical pathologist to understand current diagnostic classifications of non-small cell lung cancer and to be aware of the range of preneoplastic lesions, as well as the features useful for distinguishing bronchioloalveolar carcinoma from adenocarcinoma in small pulmonary nodules.
  • Although pleural mesothelioma has distinct features, it can also overlap histologically with adenocarcinoma, and immunohistochemistry can greatly aid in accurate diagnosis.
  • New therapies targeting molecular markers in both non-small cell lung cancer and mesothelioma rely on accurate histopathologic diagnosis of these entities.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Mesothelioma / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Diagnosis, Differential. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med. 2009 Nov;133(11):1733
  • (PMID = 19642737.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


30. Glynn C, Zakowski MF, Ginsberg MS: Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol; 2010 Mar;5(3):344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
  • PURPOSE: To identify any particular imaging features on computed tomography (CT) in patients with confirmed adenocarcinoma with bronchioloalveolar (ABAC) features and known epidermal growth factor receptor (EGFR) and KRAS mutations.
  • Seventy-seven pulmonary nodules in 64 patients with a histologic diagnosis of ABAC and known EGFR or KRAS mutation status were assessed.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / genetics. Lung Neoplasms / radiography. Mutation / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087229.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


31. Félix L, Lantuejoul S, Jankowski A, Ferretti G: [Localized pure or mixed ground-glass lung opacities]. J Radiol; 2009 Nov;90(11 Pt 2):1869-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized pure or mixed ground-glass lung opacities].
  • Localized ground-glass opacities (GGOs) have been recently individualized and account for between 2.9% and 19% of all pulmonary nodules detected in high-risk patients included in CT screening series for lung cancer.
  • These opacities, nodular, lobular or flat, correspond to benign lesions (localised infectious and inflammatory diseases, focal interstitial fibrosis, and atypical alveolar hyperplasia) or malignant lesions (bronchioloalveolar carcinoma, early-stage adenocarcinoma and sometimes metastases).
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography. Radiography, Thoracic / methods. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Algorithms. Biopsy. Clinical Trials as Topic. Diagnosis, Differential. Female. Humans. Hyperplasia. Lung / pathology. Middle Aged. Neoplasm Staging. Prognosis. Pulmonary Alveoli / pathology. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953078.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 101
  •  go-up   go-down


32. Ulmeanu R, Mihăltan F, Crişan E, Alexe M, Grigore P, Andreescu I, Galbenu P, Leonte D: [Practical issues of transbronchial lung biopsy (TLB) in pneumology]. Pneumologia; 2007 Apr-Jun;56(2):59-67
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical issues of transbronchial lung biopsy (TLB) in pneumology].
  • METHOD: We present a survey of 78 TLB which have been performed in Bronchology Service (during 2003-2005) for diffuse interstitial lung diseases--70 cases or located diseases--8 cases; TLB was not performed for solitary peripherally opacities because we have no radiological device with mobile arm (for good position of forceps).
  • RESULTS: In 78% of cases we obtained illustrative lung tissue and in 22% of cases we prelevated just bronchial wall.
  • Histological confirmation was obtained for 53% of cases; 47% of cases have as result lung tissue without significant modifications.
  • Histological diagnosis was obtain in 41% of cases.
  • The diagnosis of lung pathology was: diffuse lung fibrosis, tuberculosis, sarcoidosis stage II-III, malignant lymphoma, carcinomatosis, undifferentiated carcinoma, bronchioloalveolar carcinoma, squamous carcinoma, adenocarcinoma.
  • The international guidelines request that the TLB has to be made before the thoracoscopy or the thoracotomy; because of the small size of prelevated fragments the diagnosis sensibility is variable.
  • Our results for the 78 cases are comparable with the international data from literature both from the point of view of the diagnosis and the complications.
  • [MeSH-major] Biopsy, Needle / methods. Bronchoscopy. Lung Diseases / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / pathology. Health Surveys. Humans. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Practice Guidelines as Topic. Pulmonary Fibrosis / pathology. Sarcoidosis, Pulmonary / pathology. Sensitivity and Specificity. Tuberculosis, Pulmonary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019749.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


33. Nishiyama N, Iwata T, Nagano K, Izumi N, Tsukioka T, Tei K, Yamamoto R, Suehiro S: Lung metastases from various malignancies combined with primary lung cancer. Gen Thorac Cardiovasc Surg; 2010 Oct;58(10):538-41
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung metastases from various malignancies combined with primary lung cancer.
  • Various tumors metastasize to the lung, and they are often detected as multiple nodules.
  • We report on two cases of such multiple lung metastases combined with primary lung cancer: a myxoid liposarcoma in the right thigh and a colon cancer.
  • In each case, a pulmonary metastasectomy revealed that one of the tumors was primary lung cancer.
  • Regardless of recent advances in computed tomography for detecting small pulmonary nodules and ground-glass opacity components, which indicate possible primary lung cancer, the preoperative differential diagnosis for either metastatic or primary lung cancers is usually difficult because they are too small to obtain enough tissue for diagnosis, except by surgery.
  • When nodules are removed and diagnosed as lung metastasis combined with primary lung cancer, additional treatment should be considered depending on the prognosis of each disease.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Colonic Neoplasms / pathology. Leiomyosarcoma / secondary. Lung Neoplasms / pathology. Multiple Pulmonary Nodules / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941570.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Saad RS, Liu YL, Silverman JF: Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung. Appl Immunohistochem Mol Morphol; 2010 May;18(3):219-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung.
  • We investigated the staining pattern of commonly used basal cell/myoepithelial markers, such as p63 (a p53-homologous nuclear protein), basal cell-specific cytokeratin antibody (34betaE12, K903), and smooth muscle myosin heavy chain (SMMHC) in benign and malignant bronchioloalveolar proliferations of the lung.
  • We studied 85 lung lesions consisting of 35 bronchioloalveolar carcinoma, 30 well-differentiated adenocarcinoma, and 20 cases of benign lung lesions.
  • In normal lung, p63, K903, and SMMHC decorated the basal cells of large and small airways and occasional cells of terminal bronchioles.
  • Respiratory ciliated cells, alveolar epithelial cells, and nonepithelial cells were negative.
  • For adenocarcinoma, a majority of the cases (28/30, 93%) were negative for p63 and K903; however, SMMHC showed artifactual staining in the desmoplastic stroma in 6/30 (20%) cases.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065853.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.6.1.- / Smooth Muscle Myosins
  •  go-up   go-down


35. Sun JS, Park KJ, Sheen SS, Yoon JK, Yoon SN, Lee KB, Hwang SC: Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer; 2009 Nov;66(2):205-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
  • PURPOSE: To evaluate the clinical usefulness of fluorodeoxyglucose (FDG)-PET maximal SUV in combination with CT features for differentiation of adenocarcinoma with bronchioloalveolar carcinoma (BAC) from other subtypes of non-small cell lung cancer (NSCLC).
  • We categorized NSCLC into adenocarcinoma with BAC feature and other subtypes.
  • Finally, there were 16 cases of adenocarcinoma with BAC and 109 cases of other NSCLC subtypes included in the study.
  • Several CT features of lung cancer were analyzed, including tumor size, presence of spiculation, margin (irregular or smooth), pattern of the mass (pure solid, pure ground glass opacity and mixed), associated pleural effusion and location (center, mid and periphery).
  • The diagnostic performances of CT alone, PET alone, and combination of two modalities to predict adenocarcinoma with BAC from other subtypes of NSCLC were calculated.
  • RESULTS: A nodule with a mixed pattern with partly solid and ground glass opacity was significantly more frequent CT feature of an adenocarcinoma with BAC (8/16, 50%) as compared with the other subtypes (2/109, 1.8%) (p<0.0001).
  • Maximal SUV of adenocarcinoma with BAC (mean=7.2) was significantly lower than that of other subtypes of NSCLC (mean=13.33) (p<0.0001).
  • Sensitivity, specificity, PPV, and NPV of CT for differentiating adenocarcinoma with BAC from other subtypes was 50% (8/16), 98.2% (107/109), 80% (8/10), and 93% (107/115), respectively.
  • CONCLUSION: Careful combined assessment of the FDG-PET maximal SUV and CT findings have the potential to differentiate an adenocarcinoma with BAC from other NSCLC subtypes, such as a pure BAC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203812.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Goo JM, Kim HY, Lee JW, Lee HJ, Lee CH, Lee KW, Kim TJ, Lim KY, Park SH, Bae KT: Is the computer-aided detection scheme for lung nodule also useful in detecting lung cancer? J Comput Assist Tomogr; 2008 Jul-Aug;32(4):570-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is the computer-aided detection scheme for lung nodule also useful in detecting lung cancer?
  • OBJECTIVE: To evaluate the impact of a computer-aided diagnosis (CAD) system on the performance of observers for the detection of both lung nodules and lung cancers.
  • Database included 23 lung cancers (long diameter <20 mm), nodules stable for at least 2 years, and normal cases.
  • RESULTS: The performance of detecting lung nodules was increased significantly with CAD for all radiologists and subgroups (P < 0.01).
  • Although the overall performance of detecting lung cancers was not affected significantly with the use of CAD (P > 0.05), 4 lung cancers missed by 3 residents on their initial observation were additionally detected with CAD.
  • Eighteen of 23 lung cancers were detected by CAD itself.
  • CONCLUSIONS: The overall radiologists' performance of detecting lung nodules was improved significantly with the use of CAD, whereas no statistical significance was observed for the detection of lung cancers.
  • The use of CAD, however, contributed to the detection of additional lung cancers for less experienced readers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Computer-Assisted / methods. Lung Neoplasms / diagnosis. Radiographic Image Interpretation, Computer-Assisted / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Imaging, Three-Dimensional / methods. Lung / radiography. Male. Middle Aged. Observer Variation. Reference Standards. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664845.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Tsunezuka Y, Shimizu Y, Tanaka N, Takayanagi T, Kawano M: Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size. World J Surg; 2007 Feb;31(2):314-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size.
  • BACKGROUND: F-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) scanning has become a critically important tool in diagnosis and management of non-small-cell lung cancer.
  • However, the effectiveness of (18)F-FDG-PET as a diagnostic tool for small-sized lung cancer is controversial.
  • The purpose of this study was to examine the accuracy of( 18)F-FDG-PET in relation to Noguchi's classification in the diagnosis of small peripheral non-small-cell lung cancer.
  • METHODS: Between January 2003 and April 2006, 150 patients with peripheral lung lesions who were undergoing chest computed tomography (CT),( 18)F-FDG-PET, and operation were analyzed.
  • In 37 patients with peripheral lung cancer measuring 2.0 cm or less in the greatest diameter, the sensitivity was 51.4% and the specificity was 51.9%.
  • Among them, all 4 cases of Noguchi type A adenocarcinoma [localized bronchioloalveolar carcinoma (LBAC)], 4 of 5 type B and 8 of 17 type C were false negative, while 9 of 11 (81.8%) types D, E, and F (invasive carcinomas without a BAC component) were true positive.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging. Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Fluorodeoxyglucose F18. Lung Neoplasms / diagnostic imaging. Mixed Tumor, Malignant / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):278-84 [12167787.001]
  • [Cites] Respiration. 2003 Sep-Oct;70(5):500-6 [14665776.001]
  • [Cites] Ann Nucl Med. 2004 Feb;18(1):23-8 [15072180.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8396-405 [16293870.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73 [12192561.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):303-10 [14644518.001]
  • [Cites] Chest. 2006 Feb;129(2):393-401 [16478857.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23 [15337041.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):426-31 [16513611.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):956-60; discussion 961 [11269480.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1075-84 [9508193.001]
  • (PMID = 17219276.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


38. Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J: Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer; 2010 May;68(2):185-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
  • There is no optimal established therapy for treating advanced or recurrent adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC), and it remains unclear whether chemotherapy achieves therapeutic results comparable to those seen in the more common non-small lung carcinoma subtypes.
  • We demonstrated that demographic data, clinical characteristics and stage at presentation (extrathoracic versus lung metastasis, as well as TNM staging) did not distinguish between the two subtypes.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. DNA-Binding Proteins / metabolism. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19581016.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Quinazolines; 0 / TTF1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


39. Casali C, Rossi G, Marchioni A, Sartori G, Maselli F, Longo L, Tallarico E, Morandi U: A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol; 2010 Jun;5(6):830-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice.
  • METHODS: Retrospective analysis of resected BAC reclassified according to the 2004 World Health Organization classification of lung tumors.
  • Locally advanced nonmucinous BAC has a poor prognosis: the diagnosis of nonmucinous BAC in large tumors should be interpreted with caution given the possible presence of invasive areas in incompletely sampled tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20521350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


40. Fukui T, Sakakura N, Mori S, Hatooka S, Shinoda M, Yatabe Y, Mitsudomi T: Controversy about small peripheral lung adenocarcinomas: how should we manage them? J Thorac Oncol; 2007 Jun;2(6):546-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversy about small peripheral lung adenocarcinomas: how should we manage them?
  • In recent years, the clinical use of high-resolution computed tomography has greatly advanced the diagnosis of small lesions of the peripheral lung.
  • The noninvasive bronchioloalveolar carcinoma component with a replacement growth pattern of alveolar lining cells manifests as ground-glass opacity.
  • Bronchioloalveolar carcinoma is classified as a subset of lung adenocarcinoma, but has a distinct clinical presentation, tumor biology, and favorable prognosis.
  • Most small peripheral lung lesions including bronchioloalveolar carcinoma putatively originate from the peripheral airway epithelium, in which the epidermal growth factor receptor gene is frequently mutated.
  • As with other subsets of non-small cell lung cancer, surgical resection is a potentially curative treatment.
  • Although several authors in Japan suggest the suitability of limited resection including segmentectomy and wedge resection without any nodal dissections for these small lung adenocarcinomas, this procedure should be validated in future clinical trials.
  • [MeSH-major] Adenocarcinoma / therapy. Lung Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2007 Aug;2(8):734.
  • [ErratumIn] J Thorac Oncol. 2008 Mar;3(3):322
  • (PMID = 17545852.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


41. Kitada M, Ozawa K, Sato K, Hayashi S, Miyokawa N, Sasajima T: Clear cell carcinoma of the lung. Gen Thorac Cardiovasc Surg; 2010 Feb;58(2):87-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the lung.
  • We present here in the case of a patient who underwent resection of clear cell carcinoma of the lung, a rare histological type.
  • A screening test of the 71-year-old woman revealed a 2.0-cm lesion in S4 of the right lung with a diagnosis of bronchioloalveolar carcinoma before resection.
  • The histopathological examination showed clear, slightly acidophilic tumor cells rich in fine granular components proliferating in an alveolar fashion.
  • Immunostaining was diagnostically useful, distinguishing clear cell carcinoma from lung metastasis of renal clear cell carcinoma or clear cell squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Aged. Biopsy. Cell Differentiation. Cell Proliferation. Diagnostic Errors. Female. Humans. Immunohistochemistry. Lymph Node Excision. Neoplasm Staging. Predictive Value of Tests. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20155345.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Figiel S, de Leval L, Rousié C, Duysinx B, Louis R, Defraigne JO, Radermecker M: [Clinical case of the month. The "classic" triad presentation of mucinous bronchiolo-alveolar carcinoma]. Rev Med Liege; 2010 Nov;65(11):611-4
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical case of the month. The "classic" triad presentation of mucinous bronchiolo-alveolar carcinoma].
  • The case of a 59-year-old female complaining of cough of recent onset, abundant salty expectoration and lung condensation is presented.
  • This "triad" constitutes a rare but nearly pathognomonic presentation of mucinous bronchioloalveolar carcinoma (BAC) of the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Cough / etiology. Female. Humans. Lung / pathology. Lung / radiography. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189525.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


43. Chandan VS, Truong LD, Khurana KK: The utility of B72.3, carcinoembryonic antigen, and Leu M-1 in cell blocks: an adjunct to fine-needle aspiration diagnosis of bronchioloalveolar carcinoma of the lung. Cancer; 2005 Aug 25;105(4):246-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of B72.3, carcinoembryonic antigen, and Leu M-1 in cell blocks: an adjunct to fine-needle aspiration diagnosis of bronchioloalveolar carcinoma of the lung.
  • BACKGROUND: The distinction of bronchioloalveolar carcinoma (BAC) from atypical adenomatous hyperplasia (AAH) or reactive alveolar cell hyperplasia (RAH) can be difficult on aspiration cytology, even when cell block preparations are available.
  • METHODS: Immunostains for B72.3, CEA, and Leu M-1 were performed on cell block sections from 11 lung lesions that were diagnosed cytologically as BAC (6 lesions) and "atypical cells, cannot exclude BAC" (5 lesions).
  • RESULTS: Among the six lesions that had an unequivocal cytologic diagnosis of BAC, all sections were positive for two of three immunostains.
  • All 10 lesions that had a histologic diagnosis of AAH and 8 lesions that had a histologic diagnosis RAH were negative for B72.3, CEA, and Leu M-1.
  • CONCLUSIONS: Positive staining for at least 2 immunostains among B72.3, CEA, and Leu M-1 provided strong supportive evidence for the diagnosis of BAC, and a negative result for all 3 immunostains was helpful in excluding BAC and in differentiating BAC from AAH and RAH.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Antibodies, Neoplasm / metabolism. Antigens, CD15 / metabolism. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Lung Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15971208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, CD15; 0 / B72.3 antibody; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


44. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP, Goodglick L: A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res; 2008 Mar 1;14(5):1355-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
  • We have previously shown that the expression of several tissue kallikreins is significantly altered at the transcriptional level in lung cancer.
  • Here, we examined the clinical value of 11 members of the tissue kallikrein family as potential biomarkers for lung cancer diagnosis.
  • EXPERIMENTAL DESIGN: Serum specimens from 51 patients with non-small cell lung cancer (NSCLC) and from 50 healthy volunteers were collected.
  • CONCLUSIONS: We propose a multiparametric panel of kallikrein markers for lung cancer diagnosis with relatively good accuracy.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Tissue Kallikreins / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / blood. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / pathology. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. ROC Curve

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-86366; United States / NCI NIH HHS / CA / P50-CA90388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.35 / Tissue Kallikreins
  •  go-up   go-down


45. Ou SH, Zell JA: Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol; 2009 Oct;4(10):1202-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies.
  • BACKGROUND: Recent clinical trials have demonstrated differential survival benefit from chemotherapy regimens according to non-small cell lung cancer (NSCLC) histology.
  • The very elderly (80+ years) had the highest proportion of carcinoma NOS and cytologically diagnosed NSCLC regardless of period of diagnosis.
  • Cox proportional hazards regression analysis applied to stage 4 NSCLC patients indicated carcinoma NOS (vs. adenocarcinoma; hazard ratio 1.061, 95% confidence interval 1.039-1.083, p < 0.0001) and cytologically diagnosed NSCLC (versus histologically diagnosed NSCLC, hazard ratio 1.043, 95% confidence interval 1.024-1.062, p < 0.0001) were independent unfavorable prognostic factors for OS.
  • CONCLUSIONS: Carcinoma NOS was a common histologic diagnosis, had been increasing over time among NSCLC, and carried an independent unfavorable prognosis among stage 4 NSCLC patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / classification. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / classification. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / diagnosis. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. SEER Program. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701111.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


46. Okita R, Yamashita M, Nakata M, Teramoto N, Bessho A, Mogami H: Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy. Ann Thorac Surg; 2005 Jan;79(1):e1-2
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy.
  • Focal ground-glass opacity (GGO) on computed tomography has been reported in several disorders including inflammatory disease and primary neoplastic lesion of the lung.
  • Lung biopsy specimen demonstrated melanoma cells proliferating in a lepidic fashion along the thickened alveolar wall simulating bronchioloalveolar carcinoma.
  • Metastatic lung tumor showing GGO is uncommon.
  • [MeSH-major] Lung Neoplasms / radiography. Lung Neoplasms / secondary. Melanoma / radiography. Melanoma / secondary. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Dacarbazine / therapeutic use. Diagnosis, Differential. Female. Humans. Melanocytes / pathology. Middle Aged. Picibanil / administration & dosage. Tegafur / administration & dosage. Tomography, X-Ray Computed. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620900.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 1548R74NSZ / Tegafur; 39325-01-4 / Picibanil; 56HH86ZVCT / Uracil; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


47. Myung JK, Choe G, Chung DH, Seo JW, Jheon S, Lee CT, Chung JH: A simple inflation method for frozen section diagnosis of minute precancerous lesions of the lung. Lung Cancer; 2008 Feb;59(2):198-202
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A simple inflation method for frozen section diagnosis of minute precancerous lesions of the lung.
  • Evaluation of minute precancerous lesions of the lung by frozen section is very difficult for the pathologist as uninflated lung tissue usually shows severe atelectasis and frozen artifact.
  • We tried to inflate lung tissue with the embedding medium used for frozen section and to determine the appropriate dilution ratio of the embedding medium for optimization of frozen section morphology.
  • METHODS: The lung specimens were derived from 10 patients who underwent video-assisted thoracoscopic surgery (VATS) due to pneumothorax (four patients) and GGO (six patients) detected on high-resolution computed tomography (HRCT) at Seoul National University Bundang Hospital.
  • Lung specimens obtained from the six people with GGO detected on HRCT were submitted for intraoperative pathology consultation.
  • RESULTS: The frozen section quality of lung tissue was excellent after simple inflation with diluted embedding medium (2:3).
  • CONCLUSIONS: An inflation procedure using diluted embedding medium can make lung tissue expand well during frozen section.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Frozen Sections / methods. Lung Neoplasms / pathology. Precancerous Conditions / pathology. Solitary Pulmonary Nodule / pathology. Tissue Embedding / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Pneumothorax / surgery. Retrospective Studies. Sensitivity and Specificity. Thoracic Surgery, Video-Assisted / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905468.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


48. Arenberg D, American College of Chest Physicians: Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest; 2007 Sep;132(3 Suppl):306S-13S
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
  • OBJECTIVES: To review the current evidence on special issues relating to the diagnosis, imaging, prognosis, and treatment of bronchioloalveolar carcinoma (BAC).
  • METHODS: This guideline focuses on aspects of BAC that are unique and ways in which BAC differs importantly from other forms of non-small cell lung cancer (NSCLC).
  • Also included was a review of the 1999 World Health Organization (WHO) revised classification system for lung tumors, which established a more restrictive definition of BAC to tumors with a pure lepidic spreading pattern and no evidence of stromal, vascular, or pleural invasion.
  • RESULTS: With the notable exception of a lower likelihood of a positive positron emission tomography finding in the presence of BAC, staging, diagnosis, and treatment are the same as for other histologic subtypes of NSCLC, but additional treatment options that may prove to be equivalent, if not more effective, for more patients exist (eg, epidermal growth factor receptor tyrosine kinase inhibitor therapy, sublobar resection).
  • CONCLUSIONS: BAC is a form of adenocarcinoma with unique clinical, radiologic, and epidemiologic features.
  • The diagnosis of BAC should be reserved for tumors that meet the WHO criteria.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873176.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


49. Gao YS, Zhang DC, He J, Sun KL, Zhang DW, Zhang RG: [Diagnosis and surgical treatment for stage I non-small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):52-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment for stage I non-small-cell lung cancer].
  • OBJECTIVE: To evaluate the results of surgery and the diagnosis of stage I non-small-cell lung cancer (NSCLC).
  • The 5-year survival rates for patients with squamous-cell carcinoma, adenocarcinoma, adenosquamous and alveolar-cell carcinoma were 73.3%, 55.3%, 52.2%, 71.7%, respectively.
  • The 1-, 3-, 5-year survival rates for T1N0 were 95.0%, 83.2%, 74.3% whereas those of T2N0 lung lesions were 90.8%, 75.9%, 59.9% (P < 0.05).
  • CONCLUSION: The 5-year survival rate of pathologic stage I non-small-cell lung cancer is 66.1%.
  • The outcome of patients with squamous-cell carcinoma (73.3%) is similar to that of alveolar-cell carcinoma (71.7%) which, however, is better than that of adenocarcinoma (55.3%) or adenosquamouscarcinoma (52.5%).
  • Regular lobectomy plus radical mediastinal lymph node dissection is the appropriate management for stage I non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


50. Niang A, Bonnichon A, Ba-Fall K, Dussart C, Camara P, Vaylet F, Mbaye PS, L'Her P, Sane M, Margery J: [Lung cancer in Senegal]. Med Trop (Mars); 2007 Dec;67(6):651-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in Senegal].
  • In Africa the incidence of lung cancer is rising rapidly.
  • The purpose of this prospective study was to analyze clinical, therapeutic, and prognostic features of lung cancer patients treated at the Principal Hospital in Dakar between 2002 and 2007.
  • The histological diagnosis was squamous cell carcinoma in 23 cases, adenocarcinoma in 14, large-cell carcinoma in 17, small-cell lung cancer in 2, and bronchiolo-alveolar cancer in 1.
  • The much higher rate of histological diagnosis than in the sub-region is due mainly to the availability of trained personnel with access to bronchial endoscopy and CT-scan needle biopsy since September 2003.
  • Lung cancer is a health issue in Dakar, Senegal.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / therapy. Lung Neoplasms / epidemiology. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300532.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


51. Vidaver RM, Schachter BS: 2007 Annual Meeting of the National Lung Cancer Partnership: a summary of meeting highlights. J Thorac Oncol; 2008 Feb;3(2):190-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2007 Annual Meeting of the National Lung Cancer Partnership: a summary of meeting highlights.
  • This report presents highlights from The National Lung Cancer Partnership's Annual Meeting, held in June 2007 in Chicago.
  • It discusses recent refinements in the histologic, genetic, and epigenetic subtyping of lung cancers and suggests reasons why certain therapies benefit only a subset of lung cancer patients.
  • It also describes new molecular data about the subtype-specific differences in drug resistance among bronchioloalveolar-associated non-small cell lung cancers and discusses strategies to avoid or tackle specific drug-resistant tumors.
  • Finally, it describes new findings about epigenetic differences-specifically in DNA hypermethylation-among lung tumors, including some male/female differences, which may prove useful as biomarkers for diagnosis, prognosis, and prediction of response to treatments.
  • [MeSH-major] Lung Neoplasms
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / physiopathology. DNA Methylation. Drug Resistance, Neoplasm. Epigenesis, Genetic. Humans. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Sex Characteristics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303443.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Congresses; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


52. Aida S, Ohara I, Shimazaki H, Dai Y, Ogata S, Ozeki Y, Tamai S: Solitary peripheral ciliated glandular papillomas of the lung: a report of 3 cases. Am J Surg Pathol; 2008 Oct;32(10):1489-94
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary peripheral ciliated glandular papillomas of the lung: a report of 3 cases.
  • We report 3 cases of solitary papillomas located in peripheral regions of the lung that are extremely rare in the literature.
  • The neoplastic epithelium extended to the alveolar region and showed a similar appearance to bronchioloalveolar or papillary type adenocarcinomas.
  • For differential diagnosis, it is noteworthy that endobronchiolar papillomatous fronds constantly exist and spreading along alveolar walls is limited in adjacent alveoli in peripheral papillomas.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Bronchial Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasms, Glandular and Epithelial / pathology. Papilloma / pathology. Solitary Pulmonary Nodule / pathology
  • [MeSH-minor] Aged. Bronchi / pathology. Cilia / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pulmonary Alveoli / pathology. Respiratory Mucosa / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708941.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Matsuoka T, Sugi K, Matsuda E, Okabe K, Hirazawa K, Azuma T: [Mycobacterium avium complex (MAC) infection needed differential diagnosis of the recurrence after surgery for double lung cancer; report of a case]. Kyobu Geka; 2007 Dec;60(13):1200-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mycobacterium avium complex (MAC) infection needed differential diagnosis of the recurrence after surgery for double lung cancer; report of a case].
  • A 62-year-old woman had undergone video-assisted thoracic surgery (VATS) -right upper lobectomy and right S8 segmentectomy for double lung cancers (papillary adenocarcinoma and bronchioloalveoler carcinoma, stage IA).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Mycobacterium avium-intracellulare Infection / diagnosis. Neoplasms, Multiple Primary. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Mycobacterium Avium Complex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18078091.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Felner KJ, Wieczorek R, Kline M, Smith RL, Sidhu GS: Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules. Int J Surg Pathol; 2006 Jul;14(3):229-33
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules.
  • Thoracoscopic biopsy revealed multiple discrete nodules in the pleura and lung.
  • The latter consisted of tall columnar malignant cells arranged on alveolar surfaces in a lepidic growth pattern.
  • Mucin filled the alveolar lumina, both in the nodules and surrounding lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Hyaluronic Acid / metabolism. Male. Microscopy, Electron, Transmission. Microvilli / ultrastructure. Mucins / metabolism. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959710.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


55. De Filippo M, Onniboni M, Rusca M, Carbognani P, Ferrari L, Guazzi A, Casalini A, Verardo E, Cataldi V, Tiseo M, Sverzellati N, Chiari G, Rabaiotti E, Corsi A, Cacciani G, Sommario M, Ardizzoni A, Zompatori M: Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies. Radiol Med; 2008 Oct;113(7):945-53
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies.
  • PURPOSE: This study aimed to assess the usefulness of multiplanar reformations (MPR) during multidetector-row computed tomography (MDCT)-guided percutaneous needle biopsy of lung lesions difficult to access with the guidance of the native axial images alone owing to overlying bony structures, large vessels or pleural fissures.
  • MATERIALS AND METHODS: MDCT-guided transthoracic needle biopsy (TNB) was performed on 84 patients (55 men and 29 women; mean age 65 years) with suspected lung neoplasm by using a spiral MDCT scanner with the simultaneous acquisition of six slices per rotation.
  • We took care to ensure the shortest needle path without overlying large vessels, main bronchi, pleural fissures or bony structures; access to the lung parenchyma as perpendicular as possible to the pleural plane; and sampling of highly attenuating areas of noncalcified tissue within the lesion.
  • [MeSH-major] Biopsy, Needle / methods. Image Processing, Computer-Assisted. Lung / pathology. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Aged. Carcinoid Tumor / diagnosis. Carcinoid Tumor / pathology. Carcinoid Tumor / radiography. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / radiography. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Diagnosis, Differential. Female. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / radiography. Lymphomatoid Granulomatosis / diagnosis. Lymphomatoid Granulomatosis / pathology. Lymphomatoid Granulomatosis / radiography. Male. Mesothelioma / diagnosis. Mesothelioma / pathology. Mesothelioma / radiography. Middle Aged. Needles

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818985.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Vasile E, Tibaldi C, Chella A, Falcone A: Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol; 2008 Aug;3(8):912-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
  • BACKGROUND: Gefitinib and erlotinib are two orally active epidermal growth factor receptor tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer (NSCLC).
  • RESULTS: Four patients were women; histologic diagnosis was adenocarcinoma in four cases and bronchoalveolar carcinoma or unspecified NSCLC in two cases each.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Aged. Aged, 80 and over. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670311.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


57. Raz DJ, Kim JY, Jablons DM: Diagnosis and treatment of bronchioloalveolar carcinoma. Curr Opin Pulm Med; 2007 Jul;13(4):290-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of bronchioloalveolar carcinoma.
  • PURPOSE OF REVIEW: Bronchioloalveolar carcinoma accounts for 5% of lung cancers, although histologically mixed bronchioloalveolar carcinoma and adenocarcinoma account for up to 20%.
  • Bronchioloalveolar carcinoma histology is present in a majority of tumors found on lung-cancer screening by computed tomography.
  • We review issues surrounding the diagnosis and treatment of bronchioloalveolar carcinoma, which often differs from other types of lung cancer.
  • RECENT FINDINGS: A spectrum of disease from histologically pure bronchioloalveolar carcinoma to adenocarcinoma exists.
  • SUMMARY: An understanding of recent developments in the diagnosis and treatment of patients with bronchioloalveolar carcinoma histology is important as early detection of lung cancer becomes more common.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534175.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-03; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 65
  •  go-up   go-down


58. Shvartsbeyn M, Edelman MJ: Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1188-90
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed-induced typhlitis in non-small cell lung cancer.
  • Food and Drug Administration-approved as a second line, single-agent treatment of recurrent metastatic non-small cell lung cancer.
  • The diagnosis is supported by the findings of bowel wall thickening on computed tomographic imaging.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / adverse effects. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Typhlitis / chemically induced
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / complications. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adult. Female. Humans. Pemetrexed. Thymidylate Synthase / antagonists & inhibitors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827618.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


59. Luo BJ, Lü PX, Zhou XH, Pan JS: [CT image features of 46 cases with pneumonic-type lung cancers]. Zhonghua Zhong Liu Za Zhi; 2007 Nov;29(11):860-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT image features of 46 cases with pneumonic-type lung cancers].
  • OBJECTIVE: To analyze the CT image features of pneumonic-type lung cancer and to reduce misdiagnosis.
  • METHODS: The CT findings of 46 patients with pneumonic-type lung cancer were retrospectively reviewed, and CT image in the differential diagnosis of this special kind of disease was evaluated.
  • CONCLUSION: CT findings including lower lobe distribution, homogeneous consolidation, narrow air bronchogram, well defined ground-glass and CT angiogram are helpful in differentiating pneumonic-type lung cancer from various kinds of infection.
  • However, most of CT manifestations of pneumonic-type lung cancer are not specific.
  • Therefore, it's necessary to combine CT findings with other clinical data when making diagnosis.
  • [MeSH-major] Adenocarcinoma / radiography. Diagnostic Errors. Lung Neoplasms / radiography. Pneumonia, Bacterial / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Papillary / radiography. Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lung / radiography. Male. Middle Aged. Radiographic Image Enhancement. Tuberculosis, Pulmonary / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396648.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Zell JA, Ou SH, Ziogas A, Anton-Culver H: Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol; 2005 Nov 20;23(33):8396-405
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors.
  • RESULTS: Incident cases (11,969) of non-small-cell lung cancer (NSCLC) were analyzed, including 626 cases of BAC (5.2%).
  • This survival benefit remained after adjustment for sex, smoking status, and stage at presentation (hazard ratio for time of diagnosis before May 1999 compared with a diagnosis after May 1999 = 1.43; P = .015).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Lung Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Apr 20;24(12):1963; author reply 1963-4 [16622278.001]
  • (PMID = 16293870.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Infante M, Lutman RF, Imparato S, Di Rocco M, Ceresoli GL, Torri V, Morenghi E, Minuti F, Cavuto S, Bottoni E, Inzirillo F, Cariboni U, Errico V, Incarbone MA, Ferraroli G, Brambilla G, Alloisio M, Ravasi G: Differential diagnosis and management of focal ground-glass opacities. Eur Respir J; 2009 Apr;33(4):821-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis and management of focal ground-glass opacities.
  • Of these, 11 patients were diagnosed with benign GGOs, 19 patients had lung cancer and 10 were undetermined.
  • Overall, 18 patients underwent surgery for lung cancer.
  • The stepwise approach adopted in the present study increased the diagnostic specificity and reduced time to definitive diagnosis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Biopsy. Diagnosis, Differential. Female. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Respir J. 2009 Oct;34(4):1008-9; author reply 1009-10 [19797677.001]
  • (PMID = 19047318.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


62. Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, Jacks T, Weissleder R: Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A; 2005 Oct 4;102(40):14404-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of gene expression profiling to direct in vivo molecular imaging of lung cancer.
  • Using gene expression profiling, we identified cathepsin cysteine proteases as highly up-regulated genes in a mouse model of human lung adenocarcinoma.
  • Overexpression of cathepsin proteases in these lung tumors was confirmed by immunohistochemistry and Western blotting.
  • Therefore, an optical probe activated by cathepsin proteases was selected to detect murine lung tumors in vivo as small as 1 mm in diameter and spatially separated.
  • This study demonstrates the capability for molecular imaging of a primary lung tumor by using endogenous proteases expressed by a tumor.
  • It also highlights the feasibility of using gene expression profiling to identify molecular targets for imaging lung cancer.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4953-8 [10987312.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6330-6 [16024635.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):782-8 [10732746.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Apr;93(4):446-54 [12029284.001]
  • [Cites] Nat Med. 2002 Jul;8(7):757-60 [12091907.001]
  • [Cites] Mol Imaging. 2002 Apr-Jun;1(2):82-8 [12920848.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2767-72 [12926111.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6206-11 [14559805.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):91-100 [14695323.001]
  • [Cites] Dev Cell. 2004 Jan;6(1):7-28 [14723844.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Mod Pathol. 2004 May;17(5):538-46 [14990969.001]
  • [Cites] Cancer Cell. 2004 May;5(5):443-53 [15144952.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2573-7 [15330217.001]
  • [Cites] Pancreas. 2004 Oct;29(3):204-11 [15367886.001]
  • [Cites] J Histochem Cytochem. 1991 Apr;39(4):461-8 [2005374.001]
  • [Cites] Radiology. 1999 Sep;212(3):609-14 [10478223.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2847-51 [15517887.001]
  • [Cites] J Digit Imaging. 2004 Sep;17(3):205-16 [15534753.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • (PMID = 16183744.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA069246; United States / NCI NIH HHS / CA / P50 CA086355; United States / PHS HHS / / R2492782; United States / NCI NIH HHS / CA / R33 CA91807; United States / NCI NIH HHS / CA / R33 CA091807; United States / NCI NIH HHS / CA / P01 CA69246; United States / NCI NIH HHS / CA / P50 CA86355
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.- / Cathepsins
  • [Other-IDs] NLM/ PMC1242291
  •  go-up   go-down


63. Blons H, Côté JF, Le Corre D, Riquet M, Fabre-Guilevin E, Laurent-Puig P, Danel C: Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol; 2006 Oct;30(10):1309-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
  • In lung cancer, an association was made between drastic clinical response to epidermal growth factor receptor (EGFR) inhibitors and the presence of somatic mutations within the tyrosine kinase domain of the EGFR.
  • To go further in the characterization of the EGF pathway, we screened EGFR, ERBB2, ERBB3, KRAS, BRAF, and PIK3CA for mutations in 2 groups of White patients with nonsmall cell lung cancer (45 cancers from women and 46 cancers from men).
  • We demonstrated that EGFR mutations were linked to female sex, absence of smoking, late age at diagnosis, and adenocarcinoma (ADC) with bronchioloalveolar (BAC) features.
  • Moreover, in invasive ADC with BAC component, microdissection assays showed that mutations were retrieved in both tumor subtypes suggesting that EGFR mutations appear early in lung carcinogenesis.
  • On the contrary, KRAS mutations correlated with smoking, younger age at diagnosis, and ADC subtype regardless of BAC differentiation.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics


64. Raz DJ, Jablons DM: Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database. J Thorac Oncol; 2006 May;1(4):339-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database.
  • INTRODUCTION: Bronchioloalveolar carcinoma (BAC) is a unique subtype of non-small cell lung cancer (NSCLC) that is associated with female gender, Asian ethnicity, and never-smoking status.
  • Although BAC is commonly reported to occur more frequently in young people with lung cancer, there is a lack of evidence to support this association.
  • METHODS: We analyzed the association between age at diagnosis and NSCLC histology among 293,417 incident cases of NSCLC in the Surveillance Epidemiology, and End Results (SEER) database during the years 1973 to 2002.
  • Although a greater percentage of women and Asian patients with lung cancer were younger than 50 years old, the proportion of patients with BAC was similar to the proportion of men and non-Asians with BAC.
  • Finally, the prevalence of BAC histology among patients younger than 50 years did not change significantly after revision of the 1999 World Health Organization pathologic criteria for the diagnosis of BAC (risk ratio 0.93 versus 0.87, p = 0.31).
  • CONCLUSION: BAC is not associated with a younger mean age at diagnosis, nor is it associated with an age of less than 50 years at diagnosis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409881.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-02; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Popescu I: [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention]. Pneumologia; 2008 Oct-Dec;57(4):201-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention].
  • Early diagnosis of pulmonary cancer is crucial in the fight against this disease.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Biomarkers, Tumor / metabolism. Bronchoalveolar Lavage. Bronchoscopy / methods. Cetuximab. Early Diagnosis. Erlotinib Hydrochloride. Genes, p16. Humans. Mass Screening. Mutation. Positron-Emission Tomography. Predictive Value of Tests. Quinazolines / administration & dosage. Sensitivity and Specificity. Tomography, Optical Coherence. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186682.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; 0 / Tumor Suppressor Protein p53; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  • [Number-of-references] 48
  •  go-up   go-down


66. Chouahnia K, Brechot JM, Des-Guetz G, Saintigny P, Morere JF, Breau JL: [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer]. Rev Mal Respir; 2006 Apr;23(2 Pt 1):149-51
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
  • BACKGROUND: Carcinomatous meningitis is a major complication in Non Small Cell Lung Cancer (NSCLC).
  • OBSERVATION: We report a case of a female non-smoker with adenocarcinoma with bronchoalveolar features presenting with carcinomatous meningitis three years after the diagnosis of her primary tumour.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Chemotherapy, Adjuvant. Lung Neoplasms / pathology. Meningitis / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788439.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; S65743JHBS / gefitinib
  •  go-up   go-down


67. Tang XW, Huang HY, Zhan SH, Sun XW, Shi XL, Sun AN, Shen ZY, Kang SY, Jin ZM, Qiu HY, Miao M, Fu ZZ, Han Y, Chen SN, Xue SL, Ma X, Liu YJ, Hu XH, Zhou HF, Wu DP: [Surgical treatment and pathological findings of hematological malignancies patients complicated with lung diseases.]. Zhonghua Xue Ye Xue Za Zhi; 2009 Dec;30(12):829-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and pathological findings of hematological malignancies patients complicated with lung diseases.].
  • RESULTS: Pathological examination confirmed: aspergillus infection in 9 patients, sub-acute inflammation (fibrosis and hematoma formation) in 3, and each in 1 of pulmonary infarction with granulomatous tissue in the periphery; granulomatous inflammation with calcified tubercle; alveolar dilation and hemorrhage, interstitial fibrosis and focal vasculitis; intercostal neurilemmoma; and moderate-differentiated adenocarcinoma accompanied by intrapulmonary metastasis.
  • The coincidence rate of pre- and post-operative diagnosis was 9/14 (64.3%).
  • CONCLUSION: Hematological malignancies with persistent and/or resistant pulmonary infection, hemoptysis, or unexplained lung diseases, should be treated in time by surgery operation to effectively eliminate residual disease and obtain a definitive diagnosis, so as to create a prerequisite condition for the following treatments.
  • [MeSH-minor] Aspergillosis / diagnosis. Hematopoietic Stem Cell Transplantation. Humans. Lung Diseases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193605.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Erickson TM, Koeppe JR, Miller YE, Stuart RW, Camidge DR: Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. J Thorac Oncol; 2008 Nov;3(11):1353-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making.
  • After 14 months a solitary lung nodule developed which was excised.
  • This demonstrated an invasive adenocarcinoma with an activating epidermal growth factor receptor mutation (exon 19 deletion).
  • We discuss the diagnosis and treatment of lung cancer in HIV-positive populations and review the general and specific characteristics of bronchioloalveolar carcinoma, including response to epidermal growth factor receptor inhibitors, and known mechanisms of acquired resistance.
  • The predilection for lung cancer in HIV-positive patients, the diffuse nature of bronchioloalveolar carcinoma that can mimic infectious etiologies and the potential for dramatic responses to therapy make this an important diagnosis to consider in this setting.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. HIV / pathogenicity. HIV Infections / complications. Lung Diseases, Interstitial / diagnosis
  • [MeSH-minor] Chronic Disease. Diagnosis, Differential. Erlotinib Hydrochloride. Female. Humans. Middle Aged. Mutation / genetics. Prognosis. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors


69. Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V: Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. Diagn Cytopathol; 2007 May;35(5):257-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
  • The initial diagnosis of lung carcinoma is frequently made by fine-needle aspiration biopsy.
  • Somatic mutations of this region have been shown to predict a therapeutic response of lung carcinomas to TKI.
  • EGFR mutations have been described in adenocarcinomas of the lung, especially the bronchioloalveolar subtype, which has both cytopathologic and histopathologic definitions.
  • We identified 37 fine-needle aspiration biopsy of lung masses on which molecular analysis for EGFR mutations was available.
  • All cases were adenocarcinomas primary in the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427221.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


70. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, Lu MC, Feng AC: Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer; 2009 Nov;66(2):262-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?
  • BACKGROUND: Women with non-small cell lung cancer (NSCLC) appear to have better survival.
  • Females were younger (median age: 59.5 years vs. 65.0 years; P<0.001) and more likely to have adenocarcinoma (81% vs. 60.5%; P<0.001).
  • Patients with earlier stage, younger patients, never-smokers and females had better overall survival in univariate analyses and no significant survival difference was noted between adenocarcinoma and squamous cell carcinoma.
  • Subgroup analyses revealed the survival of never-smoker males with adenocarcinoma was similar to that of females.
  • Never-smokers with adenocarcinoma should be given special attention regardless of sex as they imply better survival with different treatment outcomes.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Factors. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299032.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


71. López Encuentra A, Pozo Rodríguez F, Martín de Nicolás JL, Villena V, Sayas Catalán J, Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía y Torácica (GCCB-S): [Bronchioloalveolar carcinoma in Spain: a rare and different form of lung cancer]. Arch Bronconeumol; 2006 Aug;42(8):399-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bronchioloalveolar carcinoma in Spain: a rare and different form of lung cancer].
  • PATIENTS AND METHODS: From a total of 2,944 cases of non-small cell lung cancer (NSCLC), 82 (3%) were BAC.
  • Other characteristics showing significant differences were the higher frequency of BAC as a chance finding and the lower likelihood of weight loss or reduced performance status at the time of diagnosis.
  • CONCLUSIONS: In Spain, among cases of lung cancer treated by surgery, BAC is very rare (3%) and displays clinical characteristics that are different from other forms of NSCLC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948993.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


72. Dillman RO, Zusman DR, McClure SE: Surgical resection and long-term survival for octogenarians who undergo surgery for non-small-cell lung cancer. Clin Lung Cancer; 2009 Mar;10(2):130-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection and long-term survival for octogenarians who undergo surgery for non-small-cell lung cancer.
  • PURPOSE: An increasing proportion of newly diagnosed non-small-cell lung cancer (NSCLC) patients are octogenarians.
  • It has been questioned whether older patients benefit from surgical resection of lung cancer to the same extent as younger patients.
  • PATIENTS AND METHODS: We conducted a single-institution, retrospective analysis of patients newly diagnosed with NSCLC from 2000-2006, who underwent surgical resection of their lung cancer in Hoag Hospital.
  • RESULTS: The proportion of patients who had local disease at diagnosis was higher for octogenarians compared with younger patients (33.6% vs. 26.6%; P = .021), but the resection rate for octogenarians was lower (64% vs. 83%; P = .0003).
  • CONCLUSION: Non-small-cell lung cancer patients < 80 years of age were less likely to undergo potentially curative surgery, but survival for octogenarians who did undergo surgical resection was comparable to younger age groups.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Age Factors. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362957.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Xu X, Chung JH, Jheon S, Sung SW, Lee CT, Lee JH, Choe G: The accuracy of frozen section diagnosis of pulmonary nodules: evaluation of inflation method during intraoperative pathology consultation with cryosection. J Thorac Oncol; 2010 Jan;5(1):39-44
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of frozen section diagnosis of pulmonary nodules: evaluation of inflation method during intraoperative pathology consultation with cryosection.
  • INTRODUCTION: Intraoperative frozen section diagnosis (FSD) is a very important pathologic examination that can determine the extent of the subsequent surgical procedure.
  • The frozen section quality of lung tissue was excellent after inflation with diluted embedding medium.
  • Inflated lung specimens harboring minute lesion displayed distinct gross appearance, which could not be palpated.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Frozen Sections / methods. Hyperplasia / diagnosis. Lung Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Solitary Pulmonary Nodule / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934776.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Nakajima Y, Kawamoto M, Koizumi K, Tajima H, Fukuda Y, Tsuchiya S, Shimizu K: An accurate diagnosis of Noguchi classification is possible after the modification of preoperative biopsy-induced fibrosis. Ann Thorac Cardiovasc Surg; 2009 Aug;15(4):221-6
MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An accurate diagnosis of Noguchi classification is possible after the modification of preoperative biopsy-induced fibrosis.
  • PURPOSE: After computed-tomography-guided needle biopsy (CTNB), the lung may undergo iatrogenic fibrosis (post-CTNB fibrosis), which can be misdiagnosed as tumor-induced fibrosis.
  • The purpose of the study was to examine if an accurate evaluation of pulmonary adenocarcinoma can be made using the Noguchi classification (type A or B vs. type C), even after CTNB.
  • MATERIALS AND METHODS: The subjects were 71 patients with primary pulmonary adenocarcinoma of 20 mm or less that had been resected surgically after CTNB.
  • CONCLUSION: An evaluation of pulmonary adenocarcinoma by Noguchi classification can be accurately performed even after CTNB.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Biopsy, Needle / adverse effects. Iatrogenic Disease. Lung Neoplasms / pathology. Pulmonary Fibrosis / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19763052.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Malhotra G, Nair N, Menon H, Gujral S, Abhyankar A, Baghel NS, Awasare S, Nabar SJ, Abhyankar S, Kand PG: Bronchoalveolar carcinoma of lung masquerading as iodine avid metastasis in a patient with minimally invasive follicular carcinoma of thyroid. Clin Nucl Med; 2008 Jan;33(1):26-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchoalveolar carcinoma of lung masquerading as iodine avid metastasis in a patient with minimally invasive follicular carcinoma of thyroid.
  • Post-therapy scan revealed diffuse uptake of radioiodine in the apical left lung.
  • An FDG PET scan showed avid uptake in the lung mass.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adenocarcinoma, Follicular / pathology. Lung Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Tomography, X-Ray Computed. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097252.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


76. Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS, Huang MH: Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg; 2007 Feb;83(2):419-24
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
  • BACKGROUND: Carcinoembryonic antigen (CEA) is one of the markers evaluated in patients with non-small cell lung cancer (NSCLC).
  • Diagnosis of adenocarcinoma and bronchoalveolar carcinoma accounted for 83.4% of these 163 female patients.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / blood. Lung Neoplasms / surgery. Preoperative Care. Pulmonary Surgical Procedures
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / blood. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Pleura / pathology. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2007 Feb;83(2):424 [17257964.001]
  • (PMID = 17257963.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


77. Feng FY, Zhang DC, Liu XY, Wang YG, Mao YS: [Surgical treatment and prognosis of synchronous double primary lung cancer: a report of 31 cases]. Ai Zheng; 2005 Feb;24(2):215-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and prognosis of synchronous double primary lung cancer: a report of 31 cases].
  • BACKGROUND & OBJECTIVE: The idea of double primary lung cancer (DPLC) has been generally accepted.
  • RESULTS: The 31 patients with synchronous DPLC accounted for 0.67% of all 4 649 patients operated for primary lung cancer in our department during the same period.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / diagnosis. Carcinoid Tumor / surgery. Female. Humans. Male. Middle Aged. Prognosis. Pulmonary Atelectasis / etiology. Respiratory Insufficiency / etiology. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694037.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • Recent advances in the treatment of pulmonary adenocarcinoma have increased the need for accurate typing of non-small cell carcinomas.
  • Immunohistochemistry for thyroid transcription factor-1 is widely used in the diagnosis of pulmonary adenocarcinomas because it marks approximately 75% of lung adenocarcinomas and is negative in most squamous cell carcinomas and adenocarcinomas of other organs.
  • It is detected in the cytoplasm of type 2 pneumocytes and alveolar macrophages and is a putative marker for pulmonary adenocarcinomas.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • Napsin A is a sensitive marker for pulmonary adenocarcinoma and is also expressed in a subset of renal cell carcinomas, particularly of the papillary type, as well as in rare cases of papillary thyroid carcinomas.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


79. Sung YM, Lee KS, Kim BT, Han J, Lee EJ: Lobar mucinous bronchioloalveolar carcinoma of the lung showing negative FDG uptake on integrated PET/CT. Eur Radiol; 2005 Oct;15(10):2075-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobar mucinous bronchioloalveolar carcinoma of the lung showing negative FDG uptake on integrated PET/CT.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2003 Sep;13(9):2122-7 [12928963.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):9-15 [9443730.001]
  • [Cites] Eur Radiol. 2004 Nov;14 (11):2092-8 [15232708.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L19-23 [15018161.001]
  • [Cites] AJR Am J Roentgenol. 2000 Apr;174(4):1005-8 [10749239.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17 (6):1345-57 [9397450.001]
  • [Cites] Eur Radiol. 2003 Sep;13(9):2119-21 [12928962.001]
  • [Cites] Semin Nucl Med. 2004 Apr;34(2):122-33 [15031812.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73 [12192561.001]
  • [Cites] Lung Cancer. 2002 Dec;38(3):261-6 [12445747.001]
  • [Cites] Eur Radiol. 2004 Jun;14(6):1118-23 [14676976.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):414-9 [8441032.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1382-3 [9293792.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 5:M134-8 [14989624.001]
  • [Cites] AJR Am J Roentgenol. 1998 Apr;170(4):935-9 [9530038.001]
  • (PMID = 15717197.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Svoboda M, Fabian P, Slabý O, Stanková M, Lakomý R, Nemecek R, Vyzula R: [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review]. Klin Onkol; 2010;23(4):224-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
  • INTRODUCTION: Bronchioloalveolar carcinoma (BAC) is an adenocarcinoma belonging to non-small cell lung carcinomas (NSCLC) that, in addition to its morphology and endobronchial spread, presents with certain specific clinical characteristics: greater incidence in women, non-smokers and younger patients, presence of malignant bronchorrhea and lower susceptibility to conventional cytostatic therapies in comparison to other subtypes of NSCLC.
  • On the other hand, nonmucinous type of BAC may show better therapeutic response to targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) erlotinib or gefitinib, as it is 5 times more frequently a carrier of EGFR gene mutations compared to conventional lung adenocarcinomas.
  • Metastases to regional and distant lymph nodes and massive involvement of skeleton with infiltrations in the bone marrow were present at the diagnosis.
  • The patient died 12 months after the diagnosis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806820.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


81. Chung JH, Choe G, Jheon S, Sung SW, Kim TJ, Lee KW, Lee JH, Lee CT: Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol; 2009 Dec;4(12):1490-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
  • INTRODUCTION: No standard guidelines detailing recommendations for the selection and treatment for multiple lung nodules with ground-glass opacity (GGO) have been established.
  • For treatment decision, we analyzed epidermal growth factor receptor (EGFR)/K-ras somatic aberrations and pathologic-radiologic correlation in multiple lung nodules presented as GGO to differentiate multifocal lesions from intrapulmonary spread.
  • METHODS: Twenty-four patients with multiple lung nodules presented as GGO were identified to investigate somatic mutations of EGFR (exon 18-21) and K-ras (codons 2, 13, and 61).
  • RESULTS: High frequency of discordant EGFR mutations (17 of 24, 70.8%) could discriminate tumor clonality (18 of 24, 75%) of multiple lung neoplastic nodules presented as GGO.
  • These findings might be a clue to establish guidelines of the multiple neoplastic lung nodules with GGO.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma in Situ / pathology. Hyperplasia / pathology. Lung Neoplasms / pathology. Mutation / genetics. Precancerous Conditions / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genotype. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Proto-Oncogene Proteins / blood. Proto-Oncogene Proteins / genetics. Tomography, X-Ray Computed. ras Proteins / blood. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19844187.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


82. Lee P, de Bree R, Brokx HA, Leemans CR, Postmus PE, Sutedja TG: Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy? Lung Cancer; 2008 Dec;62(3):309-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy?
  • OBJECTIVES: To determine if autofluorescence bronchoscopy (AF) played a role in the detection of second primary lung cancer (SPLC), and impact of SPLC on survival of patients with HNC and no cervical lymph node metastasis (N0).
  • METHODS: Patients with HNC(N0) referred for symptoms and/or radiology suspicious for lung cancer were assessed with AF.
  • Median age was 70 years, all were current or former smokers of 35 pack years, and 25 had chronic obstructive lung disease.
  • Forty-two SPLC were found; 12 (29%) affected the tracheobronchial tree and 30 (71%) involved the lung parenchyma.
  • Five radiographically occult lung cancers detected by AF were successfully treated with endobronchial therapy.
  • Lung cancer mortality was 24%.
  • Close surveillance with AF and CT for SPLC combined with aggressive treatment of early stage lung cancer might be a strategy to improve outcome.
  • [MeSH-major] Bronchoscopy. Carcinoma, Non-Small-Cell Lung / diagnosis. Head and Neck Neoplasms / pathology. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adult. Aged. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / drug therapy. Female. Fluorescence. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Prospective Studies. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / drug therapy. Smoking. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2009 Aug;65(2):255 [19410330.001]
  • (PMID = 18486989.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


83. Yoshida J, Ishii G, Yokose T, Aokage K, Hishida T, Nishimura M, Onuki T, Noguchi M, Nagai K: Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients. J Thorac Oncol; 2010 Apr;5(4):546-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Glass / chemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor / genetics. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Mutation / genetics. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Receptor, Epidermal Growth Factor / genetics. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357619.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


84. Boukakis G, Patrinou-Georgoula M, Lekarakou M, Valavanis C, Guialis A: Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer; 2010;10:434
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.
  • The altered expression pattern of hnRNP A2/B1 and/or splicing variant B1 alone in human lung cancer and their potential to serve as molecular markers for early diagnosis remain issues of intense investigation.
  • The main objective of the present study was to use paired tumour/non-tumour biopsies from patients with non-small cell lung cancer (NSCLC) to investigate the expression profiles of hnRNP A1, A2/B1 and A3 in conjunction with ASF/SF2.
  • METHODS: We combined western blotting of tissue homogenates with immunohistochemical examination of fixed tissue sections and quantification of mRNA expression levels in tumour versus adjacent normal-looking areas of the lung in the same patient.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Heterogeneous-Nuclear Ribonucleoprotein Group A-B / metabolism. Lung / metabolism. RNA, Messenger / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Aged. Blotting, Western. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Female. Humans. Immunoenzyme Techniques. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. RNA-Binding Proteins / genetics. RNA-Binding Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Serine-Arginine Splicing Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 Apr;16(4):763-7 [10717246.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4048-52 [10632338.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1896-902 [11280744.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):979-84 [11396191.001]
  • [Cites] Lung Cancer. 2001 Dec;34(3):341-50 [11714531.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):195-205 [11994740.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):215-20 [12065097.001]
  • [Cites] Lung Cancer. 2003 Apr;40(1):45-53 [12660006.001]
  • [Cites] J Pathol. 2003 May;200(1):88-94 [12692846.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):131-43 [12871776.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):179-86 [12871781.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1493-501 [14562022.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7679-88 [14633690.001]
  • [Cites] Mol Carcinog. 2004 Dec;41(4):187-96 [15390079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):9788-92 [2557628.001]
  • [Cites] Annu Rev Biochem. 1993;62:289-321 [8352591.001]
  • [Cites] Science. 1994 Jul 29;265(5172):615-21 [8036511.001]
  • [Cites] Genomics. 1995 Jan 20;25(2):365-71 [7789969.001]
  • [Cites] Exp Cell Res. 1995 Nov;221(1):187-96 [7589244.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10760-6 [8631886.001]
  • [Cites] RNA. 1998 Apr;4(4):430-44 [9630249.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1631-40 [9676837.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Oct;19(4):554-62 [9761751.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5818-24 [9865741.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2237-46 [9815620.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):399-411 [9925756.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1720-30 [10022859.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1404-7 [10197602.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):635-40 [15703818.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):643-64 [15769940.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):888-95 [15964549.001]
  • [Cites] J Cell Sci. 2005 Jul 15;118(Pt 14):3173-83 [16014382.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):85-100 [16378690.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):395-402 [17067748.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1638-42 [17363515.001]
  • [Cites] Cancer Genomics Proteomics. 2007 May-Jun;4(3):233-9 [17878526.001]
  • [Cites] Mol Carcinog. 2007 Nov;46(11):887-900 [17477362.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):1977-86 [18342629.001]
  • [Cites] Curr Med Chem. 2009;16(9):1047-61 [19275611.001]
  • [Cites] Anticancer Res. 2009 Apr;29(4):1373-82 [19414390.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Nov;23(5):636-45 [11062142.001]
  • (PMID = 20716340.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HNRNPA3 protein, human; 0 / Heterogeneous-Nuclear Ribonucleoprotein Group A-B; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / hnRNP A1; 170974-22-8 / Serine-Arginine Splicing Factors
  • [Other-IDs] NLM/ PMC2933625
  •  go-up   go-down


85. Iwanami M, Odaka M, Nakamura T, Hirata K: [Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with anti P/Q-type voltage-gated calcium channel antibody in a patient with primary double lung cancer]. Brain Nerve; 2009 Sep;61(9):1083-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with anti P/Q-type voltage-gated calcium channel antibody in a patient with primary double lung cancer].
  • We report the case of a 50-year-old man with paraneoplastic cerebellar degeneration (PCD) and Lambert-Eaton myasthenic syndrome (LEMS) associated with primary double lung cancer.
  • On the basis of the diagnosis of acute cerebelitis, he was given methylprednisolone pulse therapy followed by oral prednisolone, which gradually improved his neurological signs and symptoms.
  • The analysis of the possible etiology suggested that the PCD was induced by lung cancer, which led to ataxia.
  • A chest computed tomography scan revealed mass lesions of irregular shape and unclear margins in the upper lobe of the right lung and a small nodule tumor in the upper lobe of the left lung.
  • We performed transbronchial needle aspiration and detected the bronchioloalveolar carcinoma of the right lung.
  • A diagnosis of double primary lung cancer was made.
  • Physicians need to be aware that patients may develop PCD and LEMS associated with anti-VGCC antibody caused by small cell lung cancer, and a mass survey should be conducted and careful examinations performed.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / immunology. Autoantibodies / immunology. Calcium Channels, P-Type / immunology. Calcium Channels, Q-Type / immunology. Lambert-Eaton Myasthenic Syndrome / etiology. Lung Neoplasms / immunology. Neoplasms, Multiple Primary. Paraneoplastic Cerebellar Degeneration / etiology


86. Ou SH, Zell JA, Ziogas A, Anton-Culver H: Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer; 2007 Oct 1;110(7):1532-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.
  • BACKGROUND: Platinum-based adjuvant chemotherapy in randomized trials has failed to provide a survival benefit in patients with resected stage I nonsmall cell lung cancer (NSCLC).
  • RESULTS: Advanced age at diagnosis, male sex, low socioeconomic status (SES), nonsurgical treatment, and poor histologic grade (stage IA NSCLC: hazards ratio [HR], 1.13; 95% confidence interval [95% CI], 1.08-1.19; stage IB NSCLC: HR, 1.11; 95% CI, 1.07-1.16) were associated with increased mortality risk on multivariate analysis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Asian Americans / statistics & numerical data. California / epidemiology. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonectomy / methods. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Registries. Risk Assessment. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702091.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Koyama H, Ohno Y, Aoyama N, Onishi Y, Matsumoto K, Nogami M, Takenaka D, Nishio W, Ohbayashi C, Sugimura K: Comparison of STIR turbo SE imaging and diffusion-weighted imaging of the lung: capability for detection and subtype classification of pulmonary adenocarcinomas. Eur Radiol; 2010 Apr;20(4):790-800
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of STIR turbo SE imaging and diffusion-weighted imaging of the lung: capability for detection and subtype classification of pulmonary adenocarcinomas.
  • The ADC values showed no significant difference regarding subtype classification; however, the CRs of bronchio-alveolar carcinomas (BACs) were significantly lower than those of other types (P < 0.05).
  • [MeSH-major] Adenocarcinoma / diagnosis. Algorithms. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Lung / pathology. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Imaging. 2006 Sep 13;6:135-43 [17015238.001]
  • [Cites] Med Phys. 1987 Jan-Feb;14(1):1-37 [3031439.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):541-5 [6625722.001]
  • [Cites] Eur Radiol. 2008 Oct;18(10):2120-31 [18458913.001]
  • [Cites] Radiology. 2004 Jun;231(3):872-9 [15163823.001]
  • [Cites] Radiology. 2001 Sep;220(3):621-30 [11526259.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] Radiology. 1988 Aug;168(2):497-505 [3393671.001]
  • [Cites] J Magn Reson Imaging. 2000 Apr;11(4):343-50 [10767062.001]
  • [Cites] AJR Am J Roentgenol. 2008 Aug;191(2):464-70 [18647918.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):208-13 [12595105.001]
  • [Cites] Radiology. 2002 Aug;224(2):503-11 [12147849.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1622-35 [17515386.001]
  • [Cites] APMIS. 1989 Aug;97(8):689-98 [2669853.001]
  • [Cites] Eur Radiol. 1997;7(8):1190-4 [9377498.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):71-8 [15208113.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):73-81 [17154370.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):358-64 [18379353.001]
  • [Cites] AJR Am J Roentgenol. 2005 Oct;185(4):979-84 [16177419.001]
  • [Cites] Magn Reson Med. 1995 May;33(5):697-712 [7596275.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] Eur Radiol. 1999;9(9):1755-64 [10602947.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):763-8 [10701622.001]
  • [Cites] Stroke. 1992 May;23(5):746-54 [1374575.001]
  • [Cites] Eur Radiol. 2006 Jul;16(7):1468-77 [16557366.001]
  • [Cites] Radiology. 1986 Aug;160(2):299-305 [3726104.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):465-9 [10430155.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Radiology. 2007 May;243(2):570-7 [17400757.001]
  • (PMID = 19763578.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


88. Laskin JJ, Sandler AB, Johnson DH: Redefining bronchioloalveolar carcinoma. Semin Oncol; 2005 Jun;32(3):329-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BAC) is a subtype of non-small cell lung cancer (NSCLC) with distinct clinical and pathologic features.
  • Although BAC appears to be on a pathologic continuum with adenocarcinoma, the most recent World Health Organization (WHO) classification system has set stringent criteria for the diagnosis.
  • Though malignant, these cancers tend to be peripheral and grow in a lepedic fashion along the alveolar septae without parenchymal invasion.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar. Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988687.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


89. Yang CQ, Zhang ZC, Yu Q, Pang JX: [Clinicopathologic characteristics of metastatic carcinomas to spleen]. Zhonghua Bing Li Xue Za Zhi; 2006 May;35(5):281-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, lung was the most common primary site for splenic metastasis and accounted for 43.8% of all cases (7/16).
  • In male patients, primary lung tumor was found in 50.0% cases (6/12).
  • Histologically, undifferentiated carcinoma of lung was frequently encountered (25.0%, 4/16), including 3 cases of small cell undifferentiated carcinoma and 1 case of large cell undifferentiated carcinoma.
  • Other histologic tumor types included bronchioloalveolar carcinoma (2 cases), colonic adenocarcinoma (2 cases), ovarian serous papillary adenocarcinoma (2 cases), and prostatic adenocarcinoma (2 cases).
  • Examples of these tumors included small cell undifferentiated carcinoma (3 cases), pulmonary adenocarcinoma (1 case) and prostatic adenocarcinoma (1 case).
  • Understanding of the clinicopathologic characteristics is helpful in guiding clinical management and pathologic diagnosis.
  • [MeSH-major] Lung Neoplasms / pathology. Ovarian Neoplasms / pathology. Spleen / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Aged. Aged, 80 and over. Carcinoma, Small Cell / secondary. Colonic Neoplasms / pathology. Cystadenocarcinoma, Serous / secondary. Female. Humans. Male. Middle Aged. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776999.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Frazer G, Laing R, Lamont D: Non-bacterial thrombotic endocarditis with a negative transesophageal echocardiogram. N Z Med J; 2005 Jul 29;118(1219):U1589
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-bacterial thrombotic endocarditis is a recognised complication of malignancy (occurring in 0.3-9.3% of patients in autopsy series), and is most commonly associated with lung cancer.
  • We describe a fatal case of non-bacterial thrombotic endocarditis associated with stage IIIB adenocarcinoma of the lung in which the transoesophageal echocardiogram was negative.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / complications. Coronary Thrombosis / diagnosis. Coronary Thrombosis / etiology. Endocarditis / diagnosis. Endocarditis / etiology. Lung Neoplasms / complications


91. West H: Emerging approaches to advanced bronchioloalveolar carcinoma. Curr Treat Options Oncol; 2006 Jan;7(1):69-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BAC) is a subtype of non-small cell lung adenocarcinoma that has distinct epidemiologic, histologic, radiographic, and clinical features.
  • The strict pathologic definition requires an absence of any invasion through the basement membrane into pulmonary parenchyma, but there is a growing consensus based on recent clinical studies that this diagnosis should be considered to be based on the clinical features of diffuse ground-glass opacities with minimal or no extra-thoracic spread and histology demonstrating adenocarcinoma with a lepidic growth pattern characteristic of BAC, even if there is a component of invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343370.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 58
  •  go-up   go-down


92. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF Jr: Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol; 2006 Nov;1(9 Suppl):S20-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BAC) is a previously uncommon subset of adenocarcinoma with unique epidemiology, pathology, radiographic presentation, clinical features, and natural history compared with other non-small cell lung cancer (NSCLC) subtypes.
  • However, in a subset of patients, rapid growth and death from bilateral diffuse consolidative disease occurs within months of diagnosis or recurrence.
  • The rising incidence of BAC is also reflected in recent lung cancer screening studies employing helical computed tomography (CT), where the differential diagnosis of GGOs includes not only BAC and overt adenocarcinoma, but inflammatory disease, focal fibrosis, and atypical adenomatous hyperplasia.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Mass Screening / methods. Neoplasm Staging. Pneumonectomy / methods. Positron-Emission Tomography. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2007 Jan;2(1):11. Heelan, Robert [added]
  • (PMID = 17409997.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


93. Zielonka TM: [Bronchioloalveolar carcinoma]. Pol Merkur Lekarski; 2005 Feb;18(104):223-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BALC) is a sub-type of adenocarcinoma, accounting for 3-5% of all lung cancer cases.
  • It is characterized by peripheral location in lung parenchyma, without visible changes in main bronchi and tumor spread occurs along the walls of the peripheral airspaces without destruction of the pulmonary interstitium.
  • It is difficult to provide a correct diagnosis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Age Distribution. Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Bronchial Neoplasms / surgery. Humans. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Risk Factors. Sex Distribution. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877136.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 44
  •  go-up   go-down


94. Awab A, Hamadani M, Peyton M, Brown B: False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. Am J Med Sci; 2007 Oct;334(4):311-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positron emission tomography (PET) is becoming widely accepted as a powerful diagnostic tool for the diagnosis of lung cancer, but it has very poor sensitivity for the detection of bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC pattern, the less common form of pulmonary neoplasia.
  • PET has a reported sensitivity of over 98% in most series but misses almost two-thirds of BAC lesions, which might delay invasive testing and early diagnosis of this potentially lethal cancer.
  • Although this diagnostic limitation has been well reported in the radiology literature, the high reported sensitivity and sensitivity can give clinicians a false sense of security with negative PET scans of lung nodules.
  • The usual risk factors for bronchogenic carcinoma are less reliable for these subtypes of non-small-cell lung cancer; thus, clinicians need to have a high index of suspicion for BAC and exercise caution when making decisions on the basis of PET.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radionuclide imaging. Lung Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030191.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Metzelder SK, Reinke C, Walthers EM, Barth P, Vogelmeier C, Neubauer A, Bals R: ["Malignant" ARDS]. Internist (Berl); 2009 Oct;50(10):1272, 1274-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the second patient, lung histology revealed an adenocarcinoma of the lung.
  • Beside solid cancers and lymphomas, acute and progressive forms of inflammatory, parenchymal lung diseases (such as acute interstitial pneumonitis, acute eosinophilic pneumonia, diffuse alveolar hemorrhagia, and acute hypersensitivity pneumonitis) can manifest with this picture.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Lung Diseases, Interstitial / complications. Lung Diseases, Interstitial / diagnosis. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Respiratory Distress Syndrome, Adult / diagnosis. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Crit Care. 1994 Mar;9(1):72-81 [8199655.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):415-24 [10862050.001]
  • [Cites] Chest. 2004 Apr;125(4):1530-5 [15078770.001]
  • [Cites] Thorax. 2002 May;57(5):452-8 [11978926.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304 [11790668.001]
  • (PMID = 19562262.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Sugita M, Sagawa M, Ueda Y, Higashi K, Sakuma T: Localized bronchioloalveolar carcinoma with small foci of active fibroblastic proliferation. A report of 2 cases. Respiration; 2006;73(5):694-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on these observations, LBAC cases have been considered candidates for limited lung resection without lymph node dissection.
  • However, this surgical option requires careful validation, and an accurate diagnosis is indispensable.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Cell Proliferation. Fibroblasts / pathology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Positron-Emission Tomography. Preoperative Care. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043954.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


97. Sheikh HA, Sasatomi E, Finkelstein S, Yousem SA: Comparative mutational analysis of pulmonary scar epithelium, bronchioloalveolar carcinomas, and invasive well-differentiated pulmonary adenocarcinomas: a molecular approach to diagnostically challenging cases. Am J Surg Pathol; 2005 Oct;29(10):1267-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Discrimination of invasive well-differentiated adenocarcinoma (IAD) from reactive bronchioloalveolar epithelium entrapped in pulmonary scars (PSE) may be difficult on routine histology, especially on small biopsies.
  • These molecular differences may serve as an adjunct to histology in challenging glandular lesions of the lung.
  • [MeSH-major] Cicatrix / genetics. DNA, Neoplasm / analysis. Lung Diseases / genetics. Lung Neoplasms / genetics. Respiratory Mucosa / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. DNA Mutational Analysis. Diagnosis, Differential. Genes, Tumor Suppressor / physiology. Humans. Loss of Heterozygosity. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160467.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


98. Priest JR, Williams GM, Hill DA, Dehner LP, Jaffé A: Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol; 2009 Jan;44(1):14-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery for congenital and early childhood lung cysts is often dictated by symptoms such as respiratory distress, infection or pneumothorax.
  • Pleuropulmonary blastoma (PPB) is the most frequent malignancy associated with childhood lung cysts.
  • The earliest manifestation of PPB is a malignant lung cyst in young children, clinically and radiographically indistinguishable from benign congenital lung cysts.
  • Numerous reports of "malignancy in a congenital lung cyst" are now understood as the characteristic progression of cystic PPB.
  • Detailed family history may reveal the hallmarks of PPB in the patient or young relatives: a unique constellation of diseases including lung cysts, cystic nephroma, childhood cancers, stromal sex-chord ovarian tumors, seminomas or dysgerminomas, intestinal polyps, thyroid hyperplasias, and hamartomas.
  • Pneumothorax and multifocal/bilateral lung cysts also characterize PPB.
  • These diagnoses predict that a lung cyst is more likely PPB than a benign congenital cyst.
  • Patients fitting this pattern deserve histologic diagnosis.
  • [MeSH-major] Cysts / pathology. Lung Diseases / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Child. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Pulmonary Blastoma / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Pulmonol. 2010 Jan;45(1):103; author reply 104 [19960525.001]
  • (PMID = 19061226.001).
  • [ISSN] 1099-0496
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


99. Chhieng DC: Cytology of bronchial associated lymphoid tissue lymphoma. Diagn Cytopathol; 2008 Oct;36(10):723-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration biopsy (FNA) of the right lower lobe mass was performed and revealed atypical alveolar cells in a lymphoid background.
  • The initial cytologic interpretation was "atypical alveolar cells, probably reactive."
  • Histologic findings revealed multiple nodules of small and medium-sized lymphocytes replacing the lung parenchyma; lymphoepithelial lesions, and type II pneumocytes hyperplasia were also noted.
  • A diagnosis of bronchial associated lymphoid tissue (BALT) lymphoma was established.
  • The patient was treated with rituximab and was disease free 2 years after initial diagnosis.
  • [MeSH-major] Lung Neoplasms / pathology. Lymphoma, B-Cell / pathology. Pulmonary Alveoli / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Biopsy, Fine-Needle. Cell Proliferation. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773446.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Bearz A, Talamini R, Vaccher E, Spina M, Simonelli C, Steffan A, Berretta M, Chimienti E, Tirelli U: MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. Int J Biol Markers; 2007 Oct-Dec;22(4):307-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bronchioloalveolar carcinoma (BAC) is a histological subtype of non-small cell lung cancer (NSCLC), particularly of adenocarcinoma.
  • No tumor marker has been validated in the diagnosis and follow-up of lung cancer, in particular to predict the outcome of treatment with EGFR inhibitors.
  • PURPOSE: As CA 15-3 antigen serum levels are reported to be pathologically abnormal in adenocarcinoma of the lung, we chose this tumor marker to monitor treatment with EGFR inhibitors of patients affected by adenocarcinoma with BAC features or pure BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Biomarkers, Tumor. Carcinoma, Non-Small-Cell Lung / metabolism. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Mucin-1 / biosynthesis. Mucin-1 / physiology. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18161663.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement